Cyano Biotech is now Simris Biologics

Cyano Biotech, now Simris Biologics after its acquisition by the Simris Group in August 2022, is worldwide leading in applied R&D on cyanobacteria and microalgae. The company’s business is based on (1) natural product libraries for drug discovery (2) off-the-shelf cyanotoxin standards for analytic & bio-reagents for research (3) contract research towards the development of natural products for the pharmaceutical, (agro)chemical, and cosmetics industries. Besides its own drug discovery program, Cyano Biotech collaborates with international pharmaceutical, agrochemical and life science companies. • Key products: - Different types of natural product libraries (biomasses, crude extracts, pre-fractionated extracts, pure compounds) in MTP format for HTS - Patented Microcystin (MC)-based ADC payloads for targeted cancer therapies, with multi-modal mode of action & favorable safety profile + proven in-vitro- & in-vivo-efficacy (comprehensive pre-clinical data available) - Analytical reference standards of diverse cyanotoxins (e.g. for quantification of toxins in water bodies) and bio-reagents of bioactive natural products from cyanobacteria (e.g. for physiological & biochemical research) - Contract R&D services: e.g. Microcystin libraries with variable conjugation chemistries for coupling to linker and mAb; further ADC (or AAC) payloads based on potent cytotoxic (or anti-infective) non-ribososmal peptides from cyanobacteria (e.g. Nodularins, Cryptophycins, Largazoles, Apratoxins etc.); strain development of industrial producer strains by genetic engineering + process development & scale-up for GMP manufacturing • Core competencies: - Unique strain & compound collection, patent-protected assets and methods, from natural-product-based drug discovery and development to industrial production • Modern lab and production infrastructure: - State-of-the-art equipment for natural-product-based drug discovery & development, cultivation, downstream processing, analytics

Website

http://www.simrisbiologics.com

Externer Link zu Cyano Biotech is now Simris Biologics

Branche

Biotechnologieforschung

Größe

2–10 Beschäftigte

Hauptsitz

Berlin, Berlin

Art

Privatunternehmen

Gegründet

2004

Spezialgebiete

Discovery and Development of Natural Products from Cyanobacteria, Drug Discovery, Cosmetic Products, Dietary Supplements and Functional Foods, Agrochemicals, Colorants and Fine Chemicals, ADC Payloads, Antibody-Drug Conjugates, ADC, Toxins, Antibody-Antibiotic Conjugates, AAC, AAC Payloads, Hit-to-Lead Development, Lead Optimization, Sustainable Bio-manufacturing, Specialty Chemicals, Microalgae und Cyanobacteria